Complexity of Skeletal Muscle Degeneration: Multi-systems Pathophysiology and Organ Crosstalk in Dystrophinopathy
Overview
Authors
Affiliations
Duchenne muscular dystrophy is a highly progressive muscle wasting disorder due to primary abnormalities in one of the largest genes in the human genome, the DMD gene, which encodes various tissue-specific isoforms of the protein dystrophin. Although dystrophinopathies are classified as primary neuromuscular disorders, the body-wide abnormalities that are associated with this disorder and the occurrence of organ crosstalk suggest that a multi-systems pathophysiological view should be taken for a better overall understanding of the complex aetiology of X-linked muscular dystrophy. This article reviews the molecular and cellular effects of deficiency in dystrophin isoforms in relation to voluntary striated muscles, the cardio-respiratory system, the kidney, the liver, the gastrointestinal tract, the nervous system and the immune system. Based on the establishment of comprehensive biomarker signatures of X-linked muscular dystrophy using large-scale screening of both patient specimens and genetic animal models, this article also discusses the potential usefulness of novel disease markers for more inclusive approaches to differential diagnosis, prognosis and therapy monitoring that also take into account multi-systems aspects of dystrophinopathy. Current therapeutic approaches to combat muscular dystrophy are summarised.
Histopathological analysis of gamma sarcoglycanopathy in Moroccan patients: A case series.
Ouazzani H, Zouaidia F, Cherradi N, Karkouri M Int J Surg Case Rep. 2024; 126():110733.
PMID: 39709673 PMC: 11726778. DOI: 10.1016/j.ijscr.2024.110733.
Upadhyay V, Ray S, Panja S, Saviola A, Maluf N, Mallela K J Biol Chem. 2024; 300(12):108002.
PMID: 39551137 PMC: 11719305. DOI: 10.1016/j.jbc.2024.108002.
Molecular and Biochemical Therapeutic Strategies for Duchenne Muscular Dystrophy.
Krishna L, Prashant A, Kumar Y, Paneyala S, Patil S, Ramachandra S Neurol Int. 2024; 16(4):731-760.
PMID: 39051216 PMC: 11270304. DOI: 10.3390/neurolint16040055.
Dowling P, Trollet C, Negroni E, Swandulla D, Ohlendieck K Proteomes. 2024; 12(1).
PMID: 38250815 PMC: 10801633. DOI: 10.3390/proteomes12010004.
Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy.
Grounds M, Lloyd E J Neuromuscul Dis. 2023; 10(6):1013-1030.
PMID: 37927274 PMC: 10657680. DOI: 10.3233/JND-230161.